Moreover, our findings demonstrated that genetic and pharmacological LSD1 inhibition is synthetic lethal to proteasome inhibition in a broad panel of MM cell lines, as well as in primary MM cells regardless of disease stage, prior lines of therapy, or cytogenetic characteristics. This evidence concerns the gene KDM1A and Miyoshi myopathy.